The CHA2DS2-Vasc Score's Role as A Standalone Predictor for Suboptimal Reperfusion and Short-Term Mortality Post Primary PCI in Individuals Diagnosed with Acute ST-Segment Elevation Myocardial Infarction

Main Article Content

Aasif Hussain
Sara Bano
Khalid Iqbal
Muhammed Rafeeq Shah
Tahir Sagheer


Background: The CHA2DS2-VASc score is an established clinical prediction tool for assessing stroke risk in patients with atrial fibrillation. However, its potential utility in predicting outcomes following primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) has not been extensively explored. The no-reflow phenomenon and in-hospital mortality are critical endpoints in the management of STEMI patients undergoing PCI.

Objective: This study aimed to evaluate the independent predictive value of the CHA2DS2-VASc score for suboptimal reperfusion and short-term mortality in patients with acute STEMI undergoing primary PCI.

Methods: In a prospective cohort study involving 116 patients with confirmed STEMI at the National Institute of Cardiovascular Diseases in Karachi, participants were categorized based on their CHA2DS2-VASc score into low (<3) and high (≥3) risk groups. Primary PCI was performed following standard treatment protocols, and variables such as initial TIMI flow, thrombus grade, and lesion complexity were documented. Statistical analysis, including multivariate regression, was conducted using SPSS Version 25.

Results: Patients with a high CHA2DS2-VASc score (≥3) exhibited a significantly increased risk of no-reflow (p-value range 0.00-0.03) and in-hospital mortality (11.1%) compared to those with a low score (<3; 1.3% mortality). Other significant findings included an association between high CHA2DS2-VASc scores and larger stent lengths (28.75±5.67 mm), smaller stent diameters (2.69±0.6 mm), higher creatinine levels (1.00±0.202 mg/dL), and increased incidence of diabetes mellitus (36.1%). The odds ratio for mortality associated with a high CHA2DS2-VASc score was 1.58 (95% CI: 1.14–2.13, p-value < 0.00).

Conclusion: The CHA2DS2-VASc score is a significant independent predictor of both no-reflow post-PCI and short-term in-hospital mortality in STEMI patients. These findings suggest the score's potential role in the pre-PCI risk stratification, which could guide clinical decision-making and potentially improve patient outcomes.

Article Details

How to Cite
Hussain, A., Bano, S., Iqbal , K., Shah, M. R., & Sagheer, T. (2024). The CHA2DS2-Vasc Score’s Role as A Standalone Predictor for Suboptimal Reperfusion and Short-Term Mortality Post Primary PCI in Individuals Diagnosed with Acute ST-Segment Elevation Myocardial Infarction. Journal of Health and Rehabilitation Research, 4(1), 578–584.
Author Biographies

Aasif Hussain, National Institute of Cardiovascular Diseases (NICVD) Karachi

Fellow Interventional Cardiology, Department of Interventional Cardiology

Sara Bano, Wapda Teaching Hospital Lahore

Medical Specialist, Department of Medicine,

Khalid Iqbal , National Institute of Cardiovascular Diseases (NICVD) Karachi

Associate Professor, Department of Interventional Cardiology,

Muhammed Rafeeq Shah, National Institute of Cardiovascular Diseases (NICVD) Karachi

Post Fellow Interventional Cardiology, Department of Interventional Cardiology,

Tahir Sagheer, National Institute of Cardiovascular Diseases (NICVD) Karachi

Professor of Interventional Cardiology, Department of Interventional Cardiology,


Mannsverk JT. The epidemiology of myocardial infarction. Trends in incidence, risk factors, severity, treatment and outcomes of myocardial infarction in a general population. 2019.

Majeed H, Chowdhury YS. Percutaneous transluminal angioplasty and balloon catheters. 2020.

Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions: the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. European heart journal. 2005;26(8):804-47.

Praljak M. Suboptimal reperfusion after primary percutaneous coronary intervention: University of Zagreb. School of Medicine; 2017.

Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian heart journal. 2016;68(4):539-51.

Addison D, Bhatt DL, Fonarow FGC, Gokak FS, Grady KL, Green FLA, et al. 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2017;70(16).

Noubiap Nzeale JJ. Screening, risk stratification, and management of atrial fibrillation 2023.

Lip GY, Connolly S, Yusuf S, Shestakovska O, Flaker G, Hart R, et al. Modification of outcomes with aspirin or apixaban in relation to CHADS2 and CHA2DS2-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Circulation: Arrhythmia and Electrophysiology. 2013;6(1):31-8.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72.

Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation. 1990;82(4):1193-202.

Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.

Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Jama. 2001;285(22):2864-70.

Harrison RW, Aggarwal A, Ou F-s, Klein LW, Rumsfeld JS, Roe MT, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. The American journal of cardiology. 2013;111(2):178-84.

Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. Journal of the American College of Cardiology. 2010;55(21):2383-9.

Ben-Nun L. Medical Research in Biblical Times from the Viewpoint of Contemporary Perspective.

Ashoori A, Pourhosseini H, Ghodsi S, Salarifar M, Nematipour E, Alidoosti M, et al. CHA2DS2-VASc score as an independent predictor of suboptimal reperfusion and short-term mortality after primary PCI in patients with acute ST segment elevation myocardial infarction. Medicina. 2019;55(2):35.

Fang C, Chen Z, Zhang J, Jin X, Yang M. Association of CHA2DS2-VASC Score with in-Hospital Cardiovascular Adverse Events in Patients with Acute ST-Segment Elevation Myocardial Infarction. International Journal of Clinical Practice. 2022;2022.

Zhu W, Wu Y, Zhou Y, Liang W, Xue R, Wu Z, et al. CHA2DS2-VASc and ATRIA scores and clinical outcomes in patients with heart failure with preserved ejection fraction. Cardiovascular Drugs and Therapy. 2020;34:763-72.

Berkovitch A, Mazin I, Younis A, Shlomo N, Nof E, Goldenberg I, et al. CHA2DS2-VASc score performance to predict stroke after acute decompensated heart failure with and without reduced ejection fraction. EP Europace. 2019;21(11):1639-45.

Rozenbaum Z, Elis A, Shuvy M, Vorobeichik D, Shlomo N, Shlezinger M, et al. CHA2DS2-VASc score and clinical outcomes of patients with acute coronary syndrome. European Journal of Internal Medicine. 2016;36:57-61.

Hochman JS, Tamis JE, Thompson TD, Weaver WD, White HD, Van de Werf F, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. New England Journal of Medicine. 1999;341(4):226-32.

Chua S-K, Lo H-M, Chiu C-Z, Shyu K-G. Use of CHADS2 and CHA2DS2-VASc scores to predict subsequent myocardial infarction, stroke, and death in patients with acute coronary syndrome: data from Taiwan acute coronary syndrome full spectrum registry. PloS one. 2014;9(10):e111167.

Poci D, Hartford M, Karlsson T, Herlitz J, Edvardsson N, Caidahl K. Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest. 2012;141(6):1431-40.

Al-Thani HA, El-Menyar A, Zubaid M, Rashed WA, Ridha M, Almahmeed W, et al. Peripheral arterial disease in patients presenting with acute coronary syndrome in six middle eastern countries. International Journal of Vascular Medicine. 2011;2011.

Goldberg RJ, McCormick D, Gurwitz JH, Yarzebski J, Lessard D, Gore JM. Age-related trends in short-and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975–1995). The American journal of cardiology. 1998;82(11):1311-7.

Roger VL, Jacobsen SJ, Weston SA, Goraya TY, Killian J, Reeder GS, et al. Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994. Annals of internal medicine. 2002;136(5):341-8.